Mylan gets Fed Circ reprieve in inhaler dispute

In a win for Mylan Pharmaceuticals, a US Court of Appeals for the Federal Circuit panel has ruled it can revisit a decision that held the generic maker infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

More on this story

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

More on this story

Americas

AstraZeneca prevails in inhaler dispute

9 March 2021 AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.